Penciclovir

Drug Profile

Penciclovir

Alternative Names: BRL 3912; Denavir; Lumavir; Vectavir

Latest Information Update: 07 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Herpes simplex virus infections
  • Discontinued Herpes zoster

Most Recent Events

  • 15 Aug 2012 Renaissance Pharma acquires US rights to penciclovir from New American Therapeutics
  • 04 Oct 2010 Penciclovir sublicensed to New American Therapeutics in US
  • 11 Apr 2008 CollaGenex Pharmaceuticals has been acquired by Galderma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top